China Universal CNI BIOMEDICINE ETF (159839) last quoted at RMB 0.39, with the latest margin buying of RMB 6.3803 million

NewTimeSpace (newtimespace.com) News, As of 13:43 on August 21, 2026, the CNI Biomedicine Index (399441) fell 4.20%. The China Universal CNI BIOMEDICINE ETF (159839) last quoted at RMB 0.39.

In terms of liquidity, the China Universal CNI BIOMEDICINE ETF (159839) posted an intraday turnover rate of 9.14%, with turnover of RMB 84.5102 million. Over a longer horizon, as of August 20, the ETF's average daily turnover over the past week stood at RMB 72.0623 million.

Data shows that leveraged funds continue to build positions. The China Universal CNI BIOMEDICINE ETF (159839) posted the latest margin buying of RMB 6.3803 million, with the latest margin balance reaching RMB 40.6369 million. (Source: Wind)

As of August 20, the China Universal CNI BIOMEDICINE ETF (159839) delivered a NAV increase of 31.87% over the past 2 years. In terms of return capability, as of August 20, 2026, since its inception the ETF's highest single-month return was 27.69%, its longest streak of consecutive monthly gains was 5 months, with the longest winning-streak gain of 31.17%, and the average return in rising months was 5.71%. As of August 20, 2026, the ETF's annualized return in excess of its benchmark over the past 3 months was 9.50%.

In terms of drawdown, as of August 20, 2026, the ETF's drawdown relative to its benchmark over the past six months was 0.19%, and the number of days to recover from the drawdown was 37 days.

In terms of fees, the China Universal CNI BIOMEDICINE ETF (159839) has a management fee rate of 0.50% and a custody fee rate of 0.10%.

In terms of tracking precision, as of August 20, 2026, the ETF's tracking error over the past 5 years was 0.031%, the highest tracking precision among comparable funds.

The China Universal CNI BIOMEDICINE ETF (159839) closely tracks the CNI Biomedicine Index. The CNI Biomedicine Index uses the listed companies in the biomedical industry across the Shanghai, Shenzhen, and Beijing exchanges as its sample universe, and selects the top 30 securities as index constituents based on a composite ranking of market capitalization and liquidity, reflecting the overall performance of the biomedical industry and providing the market with an indexed investment vehicle for the sub-sector.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.